See more : Fujisash Co.,Ltd. (5940.T) Income Statement Analysis – Financial Results
Complete financial analysis of Esperion Therapeutics, Inc. (ESPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Esperion Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- HKScan Oyj (HKSAV.HE) Income Statement Analysis – Financial Results
- Kawasaki Kisen Kaisha, Ltd. (9107.T) Income Statement Analysis – Financial Results
- Brembo S.p.A. (BRBOF) Income Statement Analysis – Financial Results
- Castle Biosciences, Inc. (CSTL) Income Statement Analysis – Financial Results
- Corsair Partnering Corporation (CORS-UN) Income Statement Analysis – Financial Results
Esperion Therapeutics, Inc. (ESPR)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.esperion.com
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116.33M | 75.48M | 78.45M | 227.55M | 148.36M | 184.47M | 0.00 | 0.00 | 0.00 | 0.00 | 4.98B | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 |
| Cost of Revenue | 43.27M | 26.97M | 14.22M | 2.39M | 175.61M | 265.00K | 258.00K | 252.00K | 236.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 786.00K | 683.22K |
| Gross Profit | 73.07M | 48.51M | 64.23M | 225.16M | -27.25M | 184.21M | -258.00K | -252.00K | -236.00K | 0.00 | 4.98B | 0.00 | 0.00 | 0.00 | 0.00 | -784.00K | -683.22K |
| Gross Profit Ratio | 62.81% | 64.27% | 81.88% | 98.95% | -18.36% | 99.86% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | -39,200.00% | 0.00% |
| Research & Development | 86.11M | 118.93M | 105.98M | 146.94M | 175.61M | 171.49M | 147.60M | 57.87M | 29.80M | 25.30M | 16.01M | 8.00M | 7.81M | 21.99M | 21.45M | 21.79M | 8.48M |
| General & Administrative | 126.92M | 97.78M | 171.29M | 180.32M | 65.85M | 33.10M | 21.38M | 18.28M | 20.24M | 10.92M | 6.74M | 2.21M | 2.36M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 15.60M | 11.30M | 13.70M | 19.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 142.52M | 109.08M | 184.99M | 199.62M | 65.85M | 33.10M | 21.38M | 18.28M | 20.24M | 10.92M | 6.74M | 2.21M | 2.36M | 5.96M | 5.02M | 2.95M | 2.52M |
| Other Expenses | 0.00 | 2.65M | 3.98M | 515.00K | 4.06M | 2.78M | 2.19M | 1.55M | 776.00K | 119.00K | 194.01K | -83.65K | -75.81K | 0.00 | 0.00 | 5.00M | 3.20M |
| Operating Expenses | 228.63M | 228.01M | 290.96M | 346.55M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.20M | 10.16M | 29.24M | 29.33M | 26.79M | 11.69M |
| Cost & Expenses | 271.90M | 254.98M | 305.18M | 348.94M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.20M | 10.16M | 29.24M | 29.33M | 27.57M | 12.37M |
| Interest Income | 0.00 | 2.60M | 112.00K | 600.00K | 4.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 58.98M | 56.81M | 46.35M | 22.67M | 8.12M | 100.00K | 198.00K | 376.00K | 520.00K | 270.00K | 936.58K | 1.49M | 577.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 164.00K | 500.00K | 612.00K | 547.00K | 319.00K | 265.00K | 258.00K | 252.00K | 236.00K | 160.00K | 70.55K | 139.43K | 178.47K | -1.29M | -2.01M | -2.05M | -683.22K |
| EBITDA | -150.11M | -176.35M | -222.14M | -120.33M | -88.73M | -204.32M | -166.53M | -74.35M | -49.03M | -36.06M | -22.69M | -10.12M | -10.06M | -27.22M | -26.80M | -25.52M | -11.69M |
| EBITDA Ratio | -129.03% | -234.31% | -283.96% | -53.12% | -60.02% | -110.90% | 0.00% | 0.00% | 0.00% | 0.00% | -0.45% | 0.00% | 0.00% | 0.00% | 0.00% | -1,086,150.00% | 0.00% |
| Operating Income | -155.56M | -179.50M | -226.73M | -121.40M | -93.10M | -204.59M | -168.98M | -76.15M | -50.04M | -36.22M | -22.76M | -10.20M | -10.16M | -27.95M | -27.32M | -27.57M | -12.37M |
| Operating Income Ratio | -133.72% | -237.83% | -289.02% | -53.35% | -62.75% | -110.90% | 0.00% | 0.00% | 0.00% | 0.00% | -0.46% | 0.00% | 0.00% | 0.00% | 0.00% | -1,378,600.00% | 0.00% |
| Total Other Income/Expenses | -53.69M | -54.16M | -42.38M | -22.16M | -4.06M | 2.78M | 1.99M | 1.17M | 256.00K | -151.00K | -3.33M | -1.54M | -652.97K | -780.00K | 2.39M | -3.80M | 0.00 |
| Income Before Tax | -209.25M | -233.66M | -269.11M | -143.55M | -97.17M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -31.37M | 0.00 |
| Income Before Tax Ratio | -179.87% | -309.58% | -343.04% | -63.09% | -65.49% | -109.40% | 0.00% | 0.00% | 0.00% | 0.00% | -0.52% | 0.00% | 0.00% | 0.00% | 0.00% | -1,568,550.00% | 0.00% |
| Income Tax Expense | 0.00 | 54.16M | 49.72M | 22.64M | 11.86M | 2.88M | 2.13M | 1.67M | 1.06M | 229.00K | 1.13M | 1.40M | 501.34K | 2.07M | 468.00K | 4.10M | -331.84K |
| Net Income | -209.25M | -287.82M | -318.82M | -166.19M | -109.02M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -27.58M | -10.67M |
| Net Income Ratio | -179.87% | -381.34% | -406.42% | -73.04% | -73.48% | -109.40% | 0.00% | 0.00% | 0.00% | 0.00% | -0.52% | 0.00% | 0.00% | 0.00% | 0.00% | -1,378,800.00% | 0.00% |
| EPS | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.71 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| EPS Diluted | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.70 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| Weighted Avg Shares Out | 103.11M | 66.41M | 28.90M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.29M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
| Weighted Avg Shares Out (Dil) | 103.11M | 66.41M | 28.90M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.34M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.76 per share a year ago.
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
– FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million –
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 13, 2024, the Company granted 66 new employees 204,900 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 27, 2024.
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024 NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024
This late-January stock-trading pattern has been a winner in 30 of the past 38 years
The stock market, as measured by the S&P 500 index SPX, has broken out strongly to the upside, trading at new intraday and closing highs. The breakout came on Jan. 19, over the 4,800 level.
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the closing of its previously announced underwritten public offering of 65,205,000 shares of its common stock, including 8,505,000 shares...
Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
Esperion Therapeutics' stock gapped down after news of a stock offering but fortunately never reached the $1.50 offering price. The presentation at the JP Morgan Healthcare Conference provided little new information and failed to boost the stock. The Q&A session...
Why Is Esperion Therapeutics (ESPR) Stock Down 24% Today?
Esperion Therapeutics (NASDAQ: ESPR ) stock is falling on Friday after the pharmaceutical company announced details for a public offering of its shares. This public offering has Esperion Therapeutics selling 56.7 million shares of ESPR stock for $1.50 each.
Source: https://incomestatements.info
Category: Stock Reports